Immune Checkpoint Inhibitors and Survival Disparities by Health Insurance Coverage Among Patients with Metastatic Cancer
ICIs widened survival gaps between insured/uninsured advanced cancer patients despite improving outcomes across all insurance groups.
T-DXd Plus Pertuzumab Outperforms Standard of Care for First-Line Treatment of Advanced HER2-Positive Breast Cancer
RedirecTT-1 Trial: Talquetamab + Teclistamab for Multiple Myeloma with Extramedullary Disease
KEYTRUDA plus Padcev Significantly Improved Event-Free and Overall Survival and Pathologic Complete Response Rate for Certain Patients with Muscle-Invasive Bladder Cancer When Given Before and After Surgery
Nivolumab Plus Relatlimab vs. Nivolumab Alone for the Adjuvant Treatment of Completely Resected Stage III–IV Melanoma: Primary Results from RELATIVITY-098
Bladder Cancer
Breast Cancer
Stay Connected
TechWire Podcast
Listen to daily tech news podcast
Maecenas potenti non, turpis eget turpis gravida maecenas.
Must Read
RedirecTT-1 Trial: Talquetamab + Teclistamab for Multiple Myeloma with Extramedullary Disease
Combination bispecific antibodies achieve 79% response rate in multiple myeloma with extramedullary disease.
Subcutaneous Immunotherapies in Solid Tumors: Are We Truly Expanding Access and Efficiency?
SC immunotherapy reduces chair time from 5-7 hours to 7 minutes but faces 45% reimbursement reduction and higher drug dose…
Technology
Subcutaneous Immunotherapies in Solid Tumors: Are We Truly Expanding Access and Efficiency?
SC immunotherapy reduces chair time from 5-7 hours to 7 minutes but…
Immune Checkpoint Inhibitors and Survival Disparities by Health Insurance Coverage Among Patients with Metastatic Cancer
ICIs widened survival gaps between insured/uninsured advanced cancer patients despite improving outcomes…
Gadgets
Urinary Biomarker Test XBCM Reduces Cystoscopy in High-Grade NMIBC Surveillance
XBCM urinary biomarker test achieves 91% sensitivity and 99% NPV…
Expert Perspectives From AUA 2025: Contextualizing the Evolving Landscape of Bladder Cancer
CR rates greater than 80% achieved with TAR-200 device -…
Software
Dalpiciclib (Dalp) Plus Endocrine Therapy (ET) as Adjuvant Treatment for HR+/HER2– Early Breast Cancer (BC): The Randomized, Phase 3, DAWNA-A Trial
Dalpiciclib + ET significantly improved iDFS in HR+/HER2- early breast…
T-DXd Plus Pertuzumab Outperforms Standard of Care for First-Line Treatment of Advanced HER2-Positive Breast Cancer
T-DXd plus pertuzumab nearly doubled progression-free survival compared to standard…
Games
FDA Approves Radioembolization Therapy for Liver Cancer
Y-90 microspheres achieved 98.5% response rate and 100% local tumor control in unresectable HCC patients across multicenter trial.
Making Sense of FLOT, Durvalumab, and the Role of Real-World Tumor Biology
Total neoadjuvant therapy with FLOT may optimize outcomes, but ctDNA could guide personalized treatment decisions.
Apps
FDA Greenlights Oral Therapy for NSCLC With EGFR Exon20 Insertion Mutations
FDA approves sunvozertinib for NSCLC with EGFR exon20 insertion mutations – first…
CheckMate 77T: Perioperative Nivolumab Shows Long-Term EFS and ‘Favorable’ OS Trend in Resectable NSCLC
Perioperative nivolumab continued to demonstrate event-free survival benefits versus placebo in patients…
Impact of Glucocorticoids on Immune Checkpoint Inhibitor Efficacy and Circulating Biomarkers in Non-Small Cell Lung Cancer Patients
“Steroids were the biggest predictor of why certain immunotherapies may not be…